SAPPHIRE II trial results show sustained virologic response in 96% of treatment-experienced patients with genotype 1 hepatitis C who were treated with interferon-free, triple-drug regimen.
Desiree Cox, MBBS, PhD
Advertisement
Articles by Desiree Cox, MBBS, PhD
Advertisement
Latest Updated Articles
A New Era in Treating Chronic Hepatitis CApril 11th 2014
Advertisement
Advertisement
Trending on HCPLive
1
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
2
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
5 Hepatology Headlines You Missed in May 2026
5